Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Sales of Investments
Cash received from selling or redeeming investments.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Sales of Investments · Q3 FY2026 · quarter ended Sep 2026
Sales of investments growth accelerates
Q3 FY2026 sales of investments of $115.08M rose 11.9% year over year, ahead of the -102.4% change in trailing-twelve-month sales of investments. Sequentially, it fell 12.6% from the prior quarter. Over 3 fiscal years it compounded at +29.6% a year.
Context
- Sales of investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.9% holds above the trailing-twelve-month pace of -102.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 494.69M USD
- Year-over-year change
- +68.4%
- 4-year CAGR
- +80.5%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 494.69M | +68.4% |
| FY2024 | 2024-12-31 | 293.71M | -19.4% |
| FY2023 | 2023-12-31 | 364.5M | +60.3% |
| FY2022 | 2022-12-31 | 227.36M | +387.4% |
| FY2021 | 2021-12-31 | 46.64M | — |
Sales of Investments vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 sales of investments of $11.04M is the smallest of the 10 companies compared; the peer median is $212.37M.
- Its year-over-year change of -102.4% is the lowest of 10, against a peer median of -17.7%.
- Over three fiscal years its annual growth of +29.6% compares with a peer median of +6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $217.57B | +193061.0% | +46.7% | — | |
| LTM Jun 2026 | $1.34B | +87.1% | +18.2% | 132.6% | |
| LTM Mar 2026 | $294M | -81.2% | -20.2% | 13.5% | |
| LTM Mar 2026 | $268.88M | +47.8% | -5.7% | — | |
| LTM Mar 2026 | $212.37M | -43.4% | +50.4% | 3701.1% | |
| LTM Mar 2026 | $164.68M | +98.9% | -5.0% | 513.3% | |
| LTM Jun 2026 | $157.88M | -17.7% | -6.6% | — | |
| LTM Mar 2026 | $146M | -24.5% | +62.7% | — | |
| LTM Mar 2026 | $82M | -28.1% | — | — | |
| LTM Sep 2026 | $11.04M | -102.4% | +29.6% | — | |
| Peer median (excluding EWTX) | $212.37M | -17.7% | +6.6% | 323.0% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| Deferred Income Tax | (2.29M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.4M | 10.92M | 17.56M | 24.71M | 34.75M |
| Change in Working Capital | 4.63M | 4.09M | (1.56M) | 10.33M | (5.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.65M | 47K | (92K) | 1.74M | 272K |
| Other Working Capital | 1.98M | 4.04M | (1.47M) | 8.59M | (5.65M) |
| Other Non-Cash Items | 2.29M | (543K) | (9.52M) | (12.55M) | (7.67M) |
| Operating Cash Flow | (33.51M) | (52.64M) | (91.95M) | (109.03M) | (143.82M) |
| Capital Expenditures | (668K) | (5.55M) | (5.75M) | (1.31M) | (256K) |
| Acquisitions (Net) | 241.56K | 65.03K | 0 | 0 | 0 |
| Purchases of Investments | (288.2M) | (292.39M) | (255.87M) | (477.06M) | (527.23M) |
| Sales of Investments | 46.64M | 227.36M | 364.5M | 293.71M | 494.69M |
| Other Investing Activities | (241.56K) | (65.03K) | 0 | 0 | 0 |
| Investing Cash Flow | (242.23M) | (70.58M) | 102.89M | (184.66M) | (32.79M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 186.15M | 129.17M | 52.62M | 239.15M | 196.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 236K | 474K | 548K | 10.11M | 0 |
| Financing Cash Flow | 186.38M | 129.64M | 53.17M | 249.25M | 196.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (89.35M) | 6.43M | 64.1M | (44.43M) | 19.48M |
| Free Cash Flow | (34.18M) | (58.18M) | (97.69M) | (110.34M) | (143.82M) |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.